Cytokinetics Inc CYTK:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 11/25/22 EST
40.68UNCH (UNCH)
Close
40.68quote price arrow up+0.17 (+0.42%)
Volume
292,944
52 week range
29.26 - 55.80
Loading...
  • Open40.26
  • Day High41.00
  • Day Low40.00
  • Prev Close40.51
  • 52 Week High55.80
  • 52 Week High Date09/09/22
  • 52 Week Low29.26
  • 52 Week Low Date01/24/22

Key Stats

  • Market Cap3.85B
  • Shares Out94.63M
  • 10 Day Average Volume0.81M
  • Dividend-
  • Dividend Yield-
  • Beta1.01
  • YTD % Change-10.75

KEY STATS

  • Open40.26
  • Day High41.00
  • Day Low40.00
  • Prev Close40.51
  • 52 Week High55.80
  • 52 Week High Date09/09/22
  • 52 Week Low29.26
  • 52 Week Low Date01/24/22
  • Market Cap3.85B
  • Shares Out94.63M
  • 10 Day Average Volume0.81M
  • Dividend-
  • Dividend Yield-
  • Beta1.01
  • YTD % Change-10.75

RATIOS/PROFITABILITY

  • EPS (TTM)-3.16
  • P/E (TTM)-12.85
  • Fwd P/E (NTM)-9.10
  • EBITDA (TTM)-211.186M
  • ROE (TTM)-242.14%
  • Revenue (TTM)148.231M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-190.34%
  • Debt To Equity (MRQ)-3,822.56%

EVENTS

  • Earnings Date02/22/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cytokinetics Inc

 

Profile

MORE
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. It is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced...
John Henderson M.D.
Independent Chairman of the Board
Robert Blum
President, Chief Executive Officer, Director
Ching Jaw
Chief Financial Officer, Senior Vice President
Robert Wong
Chief Accounting Officer, Vice President
Fady Malik M.D., Ph.D.
Executive Vice President - Research and Development
Address
., 280 EAST GRAND AVENUE
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
DNLI
Denali Therapeutics Inc
29.97-0.45-1.48%
NTLA
Intellia Therapeutics Inc
49.68-0.21-0.42%
ZLAB
Zai Lab Ltd
31.72-1.66-4.97%
ROIV
Roivant Sciences Ltd
5.16+0.02+0.39%
BEAM
Beam Therapeutics Inc
44.28-1.42-3.11%